Abstract
The discovery of Helicobacter pylori (H. pylori), the curved or spiral shaped bacteria, as the main etiologic organism of chronic gastritis, peptic ulcer disease, and gastric cancer was one the most significant discoveries in gastroenterology of the twentieth century. Helicobacter infections promote infiltration of the gastric mucosa by neutrophils, macrophages, and T and B lymphocytes, and leaves the host prone to complications resulting from chronic inflammation. If left untreated, persistent gastrointestinal infections and chronic gastritis may evolve into more severe diseases, such as peptic ulcer or atrophic gastritis. In addition, infection with H. pylori increases the risk of developing gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Helicobacter pylori infections are of great concern worldwide due to increasing antimicrobial resistance and high re-infection rates. In the 1990’s scientific evaluation of natural products and ethnomedicines for the treatment of H. pylori infections began in earnest, and many natural products have been investigated over the past 20 years with promising in vitro results. This review highlights these achievements and the classes of naturally occurring compounds with activity against H. pylori. It also points out the critical need of new treatments for H. pylori infections due to increasing global resistance.
Keywords: Helicobacter pylori, ethnomedicine, gastritis, natural products, peptic ulcer disease.
Current Bioactive Compounds
Title:Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?
Volume: 8 Issue: 3
Author(s): Temitope O. Lawal, Kapil K. Soni, Brian J. Doyle, Bolanle A. Adeniyi and Gail B. Mahady
Affiliation:
Keywords: Helicobacter pylori, ethnomedicine, gastritis, natural products, peptic ulcer disease.
Abstract: The discovery of Helicobacter pylori (H. pylori), the curved or spiral shaped bacteria, as the main etiologic organism of chronic gastritis, peptic ulcer disease, and gastric cancer was one the most significant discoveries in gastroenterology of the twentieth century. Helicobacter infections promote infiltration of the gastric mucosa by neutrophils, macrophages, and T and B lymphocytes, and leaves the host prone to complications resulting from chronic inflammation. If left untreated, persistent gastrointestinal infections and chronic gastritis may evolve into more severe diseases, such as peptic ulcer or atrophic gastritis. In addition, infection with H. pylori increases the risk of developing gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. Helicobacter pylori infections are of great concern worldwide due to increasing antimicrobial resistance and high re-infection rates. In the 1990’s scientific evaluation of natural products and ethnomedicines for the treatment of H. pylori infections began in earnest, and many natural products have been investigated over the past 20 years with promising in vitro results. This review highlights these achievements and the classes of naturally occurring compounds with activity against H. pylori. It also points out the critical need of new treatments for H. pylori infections due to increasing global resistance.
Export Options
About this article
Cite this article as:
Lawal O. Temitope, Soni K. Kapil, Doyle J. Brian, Adeniyi A. Bolanle and Mahady B. Gail, Susceptibility of Helicobacter pylori to Natural Products: Can Past Research Direct Future Drug Development?, Current Bioactive Compounds 2012; 8 (3) . https://dx.doi.org/10.2174/157340712802762447
DOI https://dx.doi.org/10.2174/157340712802762447 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Meet Our Editorial Board Member
Current Vascular Pharmacology Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Antidiabetic Oils
Current Diabetes Reviews Stress and Vulnerability Due to the Care Task: An Observational Study on Older Caregivers
Current Psychopharmacology Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects
Cardiovascular & Hematological Disorders-Drug Targets Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?
Current Vascular Pharmacology Effect of Fasting Ramadan in Diabetes Control Status - Application of Extensive Diabetes Education, Serum Creatinine with HbA1c Statistical ANOVA and Regression Models to Prevent Hypoglycemia
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Sauropus androgynus Leaves for Health Benefits: Hype and the Science
The Natural Products Journal Novel Nano Drug Systems for Cardiovascular Applications
Recent Patents on Biomedical Engineering (Discontinued) The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Cardiovascular Effects of Antiretroviral Drugs: Clinical Review
Cardiovascular & Hematological Disorders-Drug Targets Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Current Pharmaceutical Design Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Pain and Obesity in the Older Adult
Current Pharmaceutical Design